Masimo Corporation (MASI)
Automate Your Wheel Strategy on MASI
With Tiblio's Option Bot, you can configure your own wheel strategy including MASI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MASI
- Rev/Share 31.7611
- Book/Share 15.0
- PB 9.2753
- Debt/Equity 0.7237
- CurrentRatio 2.8355
- ROIC -0.0914
- MktCap 7473221724.0
- FreeCF/Share 3.5167
- PFCF 39.3535
- PE -13.1946
- Debt/Assets 0.3225
- DivYield 0
- ROE -0.5914
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | MASI | BofA Securities | -- | Neutral | -- | -- | Nov. 17, 2025 |
| Reiterated | MASI | Raymond James | -- | Outperform | $170 | $194 | Dec. 27, 2024 |
News
Here's Why You Should Add Masimo Stock to Your Portfolio Now
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
MASI targets 7%-10% revenue growth through 2028, sharp margin expansion and rising cash flow as intelligent monitoring and partnerships gain traction.
Read More
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Owlet vs. Masimo: Which Medical Monitoring Stock Is the Better Buy?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Neutral
Remote and continuous patient monitoring is moving from a niche capability to a core pillar of modern healthcare, driven by aging populations, staffing shortages, and a push toward data-driven care both inside hospitals and at home. Against this backdrop, Owlet, Inc. OWLT and Masimo Corporation MASI represent two very different ways to invest in the same secular trend.
Read More
Why Masimo (MASI) is Poised to Beat Earnings Estimates Again
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Wall Street Analysts Think Masimo (MASI) Could Surge 31.06%: Read This Before Placing a Bet
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 31.1% upside potential for Masimo (MASI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
FMS or MASI: Which Is the Better Value Stock Right Now?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Instruments stocks have likely encountered both Fresenius (FMS) and Masimo (MASI). But which of these two stocks is more attractive to value investors?
Read More
Masimo Stock Declines Despite Solid Preliminary Q4 Revenues
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
MASI posts strong fourth-quarter and full-year 2025 preliminary results with revenue and EPS above estimates, driven by core healthcare momentum.
Read More
FMS or MASI: Which Is the Better Value Stock Right Now?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Masimo (MASI). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Masimo to Present in the J.P. Morgan 2026 Healthcare Conference
Published: January 07, 2026 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of i.
Read More
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
Read More
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Read More
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Masimo (MASI) is a Top-Ranked Growth Stock: Should You Buy?
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
HALPER SADEH LLC ENCOURAGES MASIMO CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Published: December 05, 2025 by: PRNewsWire
Sentiment: Neutral
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Masimo Corporation (NASDAQ: MASI) breached their fiduciary duties to shareholders.
Read More
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Here's Why Masimo (MASI) is a Strong Growth Stock
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Wall Street Analysts Believe Masimo (MASI) Could Rally 26.6%: Here's is How to Trade
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Masimo (MASI) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Knobbe Martens Guides Masimo to $634M Win Against Apple in Patent Infringement Case
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
IRVINE, Calif. , Nov. 18, 2025 /PRNewswire/ -- A team from Knobbe Martens led medical device pioneer Masimo (NASDAQ: MASI) to a victory over Apple in a dispute involving Masimo's patented heart monitoring technology.
Read More
DRC Congratulates Knobbe Martens on its $634 Million Win for Masimo
Published: November 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
DRC congratulates Knobbe Martens on a decisive jury verdict awarding its client Masimo more than $634 million in an Apple Watch patent infringement case.
Read More
3 Reasons Growth Investors Will Love Masimo (MASI)
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Masimo (MASI) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Masimo (MASI) Upgraded to Buy: Here's What You Should Know
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Masimo (MASI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
MASI Stock Gains Post Q3 Earnings and Revenue Beat, Margins Expand
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Masimo beats third-quarter 2025 earnings and revenue estimates as operating margins and profits improve on lower expenses.
Read More
Halper Sadeh LLC Encourages Masimo Corporation Shareholders to Contact the Firm to Discuss Their Rights
Published: October 23, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Masimo Corporation (NASDAQ: MASI) breached their fiduciary duties to shareholders. If you currently own Masimo stock and acquired shares on or before May 4, 2022, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more ab.
Read More
Bet On 5 Top-Ranked Stocks With Rising P/E
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Tap these five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks are The Honest Company, Dutch Bros, AIM ImmunoTech, Masimo and Cognizant Technology Solutions.
Read More
Masimo to Report Third Quarter 2025 Financial Results after Market Close on Tuesday, November 4
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2025 financial results for the period ended September 27, 2025, after the market closes on Tuesday, November 4, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering,.
Read More
Here's Why Masimo (MASI) is a Strong Growth Stock
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition.
Read More
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is the Options Market Predicting a Spike in Masimo Stock?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to MASI stock based on the movements in the options market lately.
Read More
About Masimo Corporation (MASI)
- IPO Date 2007-08-08
- Website https://www.masimo.com
- Industry Medical - Instruments & Supplies
- CEO Catherine Szyman
- Employees 3600